---
document_datetime: 2025-12-02 04:51:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tafinlar.html
document_name: tafinlar.html
version: success
processing_time: 0.1450869
conversion_datetime: 2025-12-28 19:52:38.819877
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tafinlar

[RSS](/en/individual-human-medicine.xml/66193)

##### Authorised

This medicine is authorised for use in the European Union

dabrafenib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tafinlar](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78215)
- [More information on Tafinlar](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called 'BRAF V600'. It is used for the treatment of:

- melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with another cancer medicine, trametinib;
- advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;
- advanced non-small cell lung cancer. It is used in combination with trametinib.

Tafinlar contains the active substance dabrafenib.

Expand section

Collapse section

## How is Tafinlar used?

Treatment with Tafinlar must be started and supervised by a doctor experienced in the use of cancer medicines. The medicine can only be obtained with a prescription.

Tafinlar is available as capsules (50 and 75 mg). The dose of Tafinlar either used alone or in combination with trametinib is 150 mg twice a day taken on an empty stomach (at least 1 hour before or 2 hours after a meal).

Tafinlar can be continued for as long as the patient benefits from it. After surgery for advanced melanoma, treatment is normally continued for 12 months unless the disease comes back. Treatment may need to be interrupted or stopped, or the dose reduced, if certain side effects occur.

For more information about using Tafinlar, see the package leaflet or contact your doctor or pharmacist.

## How does Tafinlar work?

The active substance in Tafinlar, dabrafenib, works by blocking BRAF, a protein involved in stimulating cell division. In melanoma and non-small cell lung cancer with the BRAF V600 mutation, the abnormal form of BRAF plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells. By blocking the action of the abnormal BRAF, Tafinlar helps to slow down the growth and spread of the cancer.

## What benefits of Tafinlar have been shown in studies?

Tafinlar has been studied in patients whose cancer had the BRAF V600 mutation.

**Melanoma**

Tafinlar was more effective than the cancer medicine dacarbazine at controlling melanoma that had spread to other parts of the body or could not be removed surgically. This was based on one main study involving 250 patients, which measured how long patients lived until their disease got worse. Patients taking Tafinlar lived on average 6.9 months before the disease got worse, compared with 2.7 months in patients given dacarbazine.

Two additional studies on melanoma that had spread to other parts of the body or could not be removed surgically looked at using the combination of Tafinlar with trametinib. In one study 423 patients were given either the combination or Tafinlar alone. Patients given the combination lived for 11 months without their disease worsening, compared with 8.8 months for those given Tafinlar alone. In a second study involving 704 patients, Tafinlar with trametinib was compared with another medicine for melanoma, vemurafenib. Patients given the combination lived 25.6 months on average, versus 18 months with vemurafenib.

In a study involving 870 patients with stage III melanoma that had been removed surgically, the combination of Tafinlar and trametinib given for 1 year was compared with placebo (a dummy treatment). Some 40% of patients treated with the combination either died or had their disease come back after an average of about 3.5 years compared with 59% of patients receiving placebo.

**Non-small cell lung cancer**

In one main study, 171 patients with non-small cell lung cancer received either Tafinlar combined with trametinib or Tafinlar alone. The main measure of effectiveness was the percentage of patients who responded completely or partially to treatment. Response to treatment was assessed using body scans and patients' clinical data. The use of Tafinlar and trametinib led to a response in over 60% of the patients, compared with 23% of patients using Tafinlar alone.

## What are the risks associated with Tafinlar?

The most common side effects with Tafinlar (which may affect more than 1 in 10 people) are papilloma (warts), headache, nausea, vomiting, hyperkeratosis (thickening and toughening of the skin), hair loss, rash, joint pain, fever and tiredness.

When Tafinlar is taken in combination with trametinib, the most common side effects (which may affect more than 1 in 5 people) are fever, tiredness, nausea, chills, headache, diarrhoea, vomiting, joint pain and rash.

For the full list of side effects and restrictions with Tafinlar, see the package leaflet.

## Why is Tafinlar authorised in the EU?

The European Medicines Agency decided that Tafinlar's benefits in cancers that carry the BRAF V600 mutation are greater than its risks and it can be authorised for use in the EU. The Agency considered that Tafinlar when used alone or in combination with trametinib had shown clinically relevant benefit in patients with advanced non-small cell lung cancer or with melanoma that had spread or could not be removed surgically. The Agency also found it to be of benefit in patients with advanced melanoma that had been removed surgically. Tafinlar's side effects were considered acceptable and manageable with appropriate measures.

## What measures are being taken to ensure the safe and effective use of Tafinlar?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tafinlar have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tafinlar are continuously monitored. Side effects reported with Tafinlar are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tafinlar

Tafinlar received a marketing authorisation valid throughout the EU on 26 August 2013.

Tafinlar : EPAR - Medicine overview

Reference Number: EMA/538918/2013

English (EN) (82.66 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 11/09/2018

[View](/en/documents/overview/tafinlar-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-929)

български (BG) (131.01 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/bg/documents/overview/tafinlar-epar-medicine-overview_bg.pdf)

español (ES) (107.48 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/es/documents/overview/tafinlar-epar-medicine-overview_es.pdf)

čeština (CS) (126.62 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/cs/documents/overview/tafinlar-epar-medicine-overview_cs.pdf)

dansk (DA) (107.22 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/da/documents/overview/tafinlar-epar-medicine-overview_da.pdf)

Deutsch (DE) (108.18 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/de/documents/overview/tafinlar-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.58 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/et/documents/overview/tafinlar-epar-medicine-overview_et.pdf)

ελληνικά (EL) (137.15 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/el/documents/overview/tafinlar-epar-medicine-overview_el.pdf)

français (FR) (108.45 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/fr/documents/overview/tafinlar-epar-medicine-overview_fr.pdf)

hrvatski (HR) (122.01 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/hr/documents/overview/tafinlar-epar-medicine-overview_hr.pdf)

italiano (IT) (107.43 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/it/documents/overview/tafinlar-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (128.55 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/lv/documents/overview/tafinlar-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (126.42 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/lt/documents/overview/tafinlar-epar-medicine-overview_lt.pdf)

magyar (HU) (122.03 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/hu/documents/overview/tafinlar-epar-medicine-overview_hu.pdf)

Malti (MT) (127.71 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/mt/documents/overview/tafinlar-epar-medicine-overview_mt.pdf)

Nederlands (NL) (107.6 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/nl/documents/overview/tafinlar-epar-medicine-overview_nl.pdf)

polski (PL) (127.25 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/pl/documents/overview/tafinlar-epar-medicine-overview_pl.pdf)

português (PT) (107.49 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/pt/documents/overview/tafinlar-epar-medicine-overview_pt.pdf)

română (RO) (125.1 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/ro/documents/overview/tafinlar-epar-medicine-overview_ro.pdf)

slovenčina (SK) (125.41 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/sk/documents/overview/tafinlar-epar-medicine-overview_sk.pdf)

slovenščina (SL) (122.26 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/sl/documents/overview/tafinlar-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.09 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/fi/documents/overview/tafinlar-epar-medicine-overview_fi.pdf)

svenska (SV) (106.93 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

11/09/2018

[View](/sv/documents/overview/tafinlar-epar-medicine-overview_sv.pdf)

Tafinlar : EPAR - Risk management plan

English (EN) (1.39 MB - PDF)

**First published:** 11/09/2018

**Last updated:** 17/06/2025

[View](/en/documents/rmp/tafinlar-epar-risk-management-plan_en.pdf)

## Product information

Tafinlar : EPAR - Product Information

English (EN) (823.62 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 04/11/2025

[View](/en/documents/product-information/tafinlar-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-47)

български (BG) (990.39 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/bg/documents/product-information/tafinlar-epar-product-information_bg.pdf)

español (ES) (927.17 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/es/documents/product-information/tafinlar-epar-product-information_es.pdf)

čeština (CS) (973.23 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/cs/documents/product-information/tafinlar-epar-product-information_cs.pdf)

dansk (DA) (874.85 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/da/documents/product-information/tafinlar-epar-product-information_da.pdf)

Deutsch (DE) (878.91 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/de/documents/product-information/tafinlar-epar-product-information_de.pdf)

eesti keel (ET) (842.89 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/et/documents/product-information/tafinlar-epar-product-information_et.pdf)

ελληνικά (EL) (1 MB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/el/documents/product-information/tafinlar-epar-product-information_el.pdf)

français (FR) (959.01 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/fr/documents/product-information/tafinlar-epar-product-information_fr.pdf)

hrvatski (HR) (1.06 MB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/hr/documents/product-information/tafinlar-epar-product-information_hr.pdf)

íslenska (IS) (822.15 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/is/documents/product-information/tafinlar-epar-product-information_is.pdf)

italiano (IT) (904.72 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/it/documents/product-information/tafinlar-epar-product-information_it.pdf)

latviešu valoda (LV) (935.52 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/lv/documents/product-information/tafinlar-epar-product-information_lv.pdf)

lietuvių kalba (LT) (874.12 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/lt/documents/product-information/tafinlar-epar-product-information_lt.pdf)

magyar (HU) (906.04 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/hu/documents/product-information/tafinlar-epar-product-information_hu.pdf)

Malti (MT) (995.26 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/mt/documents/product-information/tafinlar-epar-product-information_mt.pdf)

Nederlands (NL) (893.37 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/nl/documents/product-information/tafinlar-epar-product-information_nl.pdf)

norsk (NO) (875.3 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/no/documents/product-information/tafinlar-epar-product-information_no.pdf)

polski (PL) (939.6 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/pl/documents/product-information/tafinlar-epar-product-information_pl.pdf)

português (PT) (849.39 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/pt/documents/product-information/tafinlar-epar-product-information_pt.pdf)

română (RO) (935.17 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/ro/documents/product-information/tafinlar-epar-product-information_ro.pdf)

slovenčina (SK) (952.42 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/sk/documents/product-information/tafinlar-epar-product-information_sk.pdf)

slovenščina (SL) (945.94 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/sl/documents/product-information/tafinlar-epar-product-information_sl.pdf)

Suomi (FI) (827.19 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/fi/documents/product-information/tafinlar-epar-product-information_fi.pdf)

svenska (SV) (802.97 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

04/11/2025

[View](/sv/documents/product-information/tafinlar-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000308071 03/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tafinlar : EPAR - All Authorised presentations

English (EN) (41.53 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 18/09/2013

[View](/en/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-1000)

български (BG) (46.69 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/bg/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.01 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/es/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_es.pdf)

čeština (CS) (15.71 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/cs/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.94 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/da/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.18 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/de/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (51.09 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/et/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.54 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/el/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_el.pdf)

français (FR) (18.29 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/fr/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.59 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/hr/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.02 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/is/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.04 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/it/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.46 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/lv/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.82 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/lt/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27.12 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/hu/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.19 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/mt/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.66 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/nl/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.78 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/no/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.74 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/pl/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.12 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/pt/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_pt.pdf)

română (RO) (27.19 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/ro/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.6 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/sk/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.46 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/sl/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.94 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/fi/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (78.2 KB - PDF)

**First published:**

18/09/2013

**Last updated:**

18/09/2013

[View](/sv/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tafinlar Active substance dabrafenib mesilate International non-proprietary name (INN) or common name dabrafenib Therapeutic area (MeSH) Melanoma Anatomical therapeutic chemical (ATC) code L01EC02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Melanoma**

Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).

**Adjuvant treatment of melanoma**

Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

**Non-small cell lung cancer (NSCLC)**

Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

## Authorisation details

EMA product number EMEA/H/C/002604 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 27/06/2013 Marketing authorisation issued 26/08/2013 Revision 38

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tafinlar : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.65 KB - PDF)

**First published:** 23/07/2025

**Last updated:** 04/11/2025

[View](/en/documents/procedural-steps-after/tafinlar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tafinlar : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (268.36 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 23/07/2025

[View](/en/documents/procedural-steps-after/tafinlar-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tafinlar-H-C-PSUSA-00010084-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/154380/2025

English (EN) (116.5 KB - PDF)

**First published:** 17/06/2025

[View](/en/documents/scientific-conclusion/tafinlar-h-c-psusa-00010084-202405-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Tafinlar-PSUSA-00010084-201808: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/271621/2019

English (EN) (113.89 KB - PDF)

**First published:** 04/06/2019

[View](/en/documents/scientific-conclusion/tafinlar-psusa-00010084-201808-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tafinlar -H-C-WS-1274: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/550929/2019

English (EN) (4.23 MB - PDF)

**First published:** 11/09/2018

**Last updated:** 11/09/2018

[View](/en/documents/variation-report/tafinlar-h-c-ws-1274-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tafinlar (WS-1274)

Adopted

Reference Number: EMA/CHMP/457561/2018

English (EN) (71.02 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar-ws-1274_en.pdf)

Tafinlar-H-C-PSUSA-00010084-201608 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/395587/2017

English (EN) (76.97 KB - PDF)

**First published:** 21/06/2017

**Last updated:** 21/06/2017

[View](/en/documents/scientific-conclusion/tafinlar-h-c-psusa-00010084-201608-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Tafinlar-H-C-WS-0996 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/240244/2017

English (EN) (2.32 MB - PDF)

**First published:** 22/05/2017

**Last updated:** 22/05/2017

[View](/en/documents/variation-report/tafinlar-h-c-ws-0996-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tafinlar

Adopted

Reference Number: EMA/CHMP/120396/2017

English (EN) (67.9 KB - PDF)

**First published:** 24/02/2017

**Last updated:** 24/02/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar_en.pdf)

Tafinlar-H-C-2604-WS-0736 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/589140/2015

English (EN) (14.12 MB - PDF)

**First published:** 03/11/2015

**Last updated:** 03/11/2015

[View](/en/documents/variation-report/tafinlar-h-c-2604-ws-0736-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tafinlar

Adopted

Reference Number: EMA/CHMP/444359/2015

English (EN) (66.74 KB - PDF)

**First published:** 24/07/2015

**Last updated:** 24/07/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar_en.pdf-0)

Tafinlar-H-C-2604-PSUV-0005: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/750482/2014

English (EN) (65.82 KB - PDF)

**First published:** 22/01/2015

**Last updated:** 22/01/2015

[View](/en/documents/scientific-conclusion/tafinlar-h-c-2604-psuv-0005-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tafinlar : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/242419/2013

English (EN) (1.59 MB - PDF)

**First published:** 18/09/2013

**Last updated:** 18/09/2013

[View](/en/documents/assessment-report/tafinlar-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tafinlar

Adopted

Reference Number: EMA/CHMP/339899/2013

English (EN) (68.1 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tafinlar_en.pdf)

#### News on Tafinlar

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2017) 24/02/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Tafinlar : EPAR - Product information - tracked changes

English (EN) (774.92 KB - DOCX)

**First published:** 23/07/2025

[View](/en/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-155)

български (BG) (813.69 KB - DOCX)

**First published:**

23/07/2025

[View](/bg/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_bg.docx)

español (ES) (870.11 KB - DOCX)

**First published:**

23/07/2025

[View](/es/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_es.docx)

čeština (CS) (772.87 KB - DOCX)

**First published:**

23/07/2025

[View](/cs/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (765.45 KB - DOCX)

**First published:**

23/07/2025

[View](/da/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (807.56 KB - DOCX)

**First published:**

23/07/2025

[View](/de/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (733.5 KB - DOCX)

**First published:**

23/07/2025

[View](/et/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (773.86 KB - DOCX)

**First published:**

23/07/2025

[View](/el/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_el.docx)

français (FR) (783.67 KB - DOCX)

**First published:**

23/07/2025

[View](/fr/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (807.77 KB - DOCX)

**First published:**

23/07/2025

[View](/hr/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (740.92 KB - DOCX)

**First published:**

23/07/2025

[View](/is/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_is.docx)

italiano (IT) (797.44 KB - DOCX)

**First published:**

23/07/2025

[View](/it/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (747.7 KB - DOCX)

**First published:**

23/07/2025

[View](/lv/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (776.91 KB - DOCX)

**First published:**

23/07/2025

[View](/lt/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (837.77 KB - DOCX)

**First published:**

23/07/2025

[View](/hu/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (773.78 KB - DOCX)

**First published:**

23/07/2025

[View](/mt/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (796.37 KB - DOCX)

**First published:**

23/07/2025

[View](/nl/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (797.52 KB - DOCX)

**First published:**

23/07/2025

[View](/no/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_no.docx)

polski (PL) (791.33 KB - DOCX)

**First published:**

23/07/2025

[View](/pl/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_pl.docx)

português (PT) (768.72 KB - DOCX)

**First published:**

23/07/2025

[View](/pt/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_pt.docx)

română (RO) (847.13 KB - DOCX)

**First published:**

23/07/2025

[View](/ro/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (784.01 KB - DOCX)

**First published:**

23/07/2025

[View](/sk/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (722.92 KB - DOCX)

**First published:**

23/07/2025

[View](/sl/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (760.83 KB - DOCX)

**First published:**

23/07/2025

[View](/fi/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (757.63 KB - DOCX)

**First published:**

23/07/2025

[View](/sv/documents/product-information-tracked-changes/tafinlar-epar-product-information-tracked-changes_sv.docx)

#### More information on Tafinlar

- [EMEA-001147-PIP01-11-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001147-pip01-11-m07)
- [Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000567)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/11/2025

## Share this page

[Back to top](#main-content)